AAPL 242.195 -3.2845% MSFT 415.4 -1.4472% NVDA 136.11 1.3553% GOOGL 188.45 -0.449% GOOG 189.67 -0.4043% AMZN 218.77 -0.2826% META 592.1525 1.1345% AVGO 230.54 -0.5607% TSLA 377.02 -6.6412% TSM 199.64 1.0887% LLY 774.59 0.3355% V 312.71 -1.0537% JPM 239.57 -0.0584% UNH 504.27 -0.3143% NVO 87.56 1.7903% WMT 89.7 -0.7194% LVMUY 128.99 -1.3008% XOM 107.02 -0.5113% LVMHF 645.0 -1.7816% MA 518.315 -1.5677%
Last update at 2024-12-31T14:30:00Z
Brookfield reaffirms its interest in Grifols, ask more time for analysis, sources say
Mon 30 Sep 24, 10:15 AMGrifols Investor Group With 7.7% Holding Seeks Seat on Board
Thu 19 Sep 24, 08:00 PMOrange, Grifols Egypt Team Up to Advance Egypt's Healthcare System
Fri 13 Sep 24, 02:18 PMGrifols Holders Call on Family, Brookfield to Offer ‘Fair Price’
Tue 10 Sep 24, 05:37 PMGrifols Postpones Capital Markets Day Amid Potential Takeover
Tue 03 Sep 24, 09:41 AMBrookfield Courts Sovereign Funds to Join Grifols Takeover Bid
Thu 29 Aug 24, 04:22 PMThis Reviled Pharmaceutical Firm Holds Promise of a Healthier Future
Mon 26 Aug 24, 11:00 AMWhy Grifols (GRFS) Stock Price Moved Up 7% on Wednesday
Thu 22 Aug 24, 03:01 PMBrookfield in talks with banks for funding Grifols' takeover bid, sources say
Wed 21 Aug 24, 04:19 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 361.26M | 350.45M | 878.63M | 817.10M | 725.84M |
| Minority interest | -62.86700M | -82.52400M | 1611.66M | 2023.65M | 471.05M |
| Net income | 208.28M | 182.80M | 708.99M | 625.15M | 596.64M |
| Selling general administrative | 1190.42M | 1061.51M | 985.62M | 942.82M | 814.77M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 2231.53M | 1962.60M | 2255.16M | 2341.23M | 2049.56M |
| Reconciled depreciation | 407.86M | 359.77M | 321.53M | 302.45M | 228.61M |
| Ebit | 704.16M | 595.62M | 1037.60M | 1187.44M | 977.97M |
| Ebitda | 1112.03M | 955.39M | 1359.13M | 1489.89M | 1206.58M |
| Depreciation and amortization | 407.86M | 359.77M | 321.53M | 302.45M | 228.61M |
| Non operating income net other | - | - | - | 0.00000M | 0.00000M |
| Operating income | 805.68M | 595.06M | 996.13M | 1131.37M | 994.12M |
| Other operating expenses | 5361.77M | 4370.61M | 4364.70M | 3976.30M | 3492.60M |
| Interest expense | 362.63M | 233.81M | 222.92M | 324.38M | 274.16M |
| Tax provision | 90.11M | 85.13M | 169.64M | 168.46M | 131.44M |
| Interest income | 33.86M | 11.55M | 8.02M | 114.20M | 13.99M |
| Net interest income | -462.66500M | -266.44300M | -241.61800M | -228.76800M | -279.27800M |
| Extraordinary items | - | - | - | 0.00000M | 0.00000M |
| Non recurring | - | - | - | 0.00000M | 0.00000M |
| Other items | - | - | - | 0.00000M | 0.00000M |
| Income tax expense | 90.11M | 85.13M | 169.64M | 168.46M | 131.44M |
| Total revenue | 6063.97M | 4933.12M | 5340.04M | 5098.69M | 4486.72M |
| Total operating expenses | 1529.33M | 1400.09M | 1279.83M | 1218.84M | 1055.44M |
| Cost of revenue | 3832.44M | 2970.52M | 3084.87M | 2757.46M | 2437.16M |
| Total other income expense net | 121.72M | 54.39M | 144.91M | -76.52200M | 11.00M |
| Discontinued operations | - | - | - | 0.00000M | 0.00000M |
| Net income from continuing ops | 271.15M | 265.33M | 708.99M | 648.64M | 594.41M |
| Net income applicable to common shares | 208.28M | 182.80M | 618.55M | 625.15M | 596.64M |
| Preferred stock and other adjustments | - | - | - | 0.00000M | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 21533.98M | 19233.83M | 15274.78M | 15542.61M | 12477.05M |
| Intangible assets | 2949.15M | 1636.95M | 1557.65M | 1433.53M | 1385.54M |
| Earning assets | - | - | - | - | - |
| Other current assets | 81.81M | 64.08M | 51.75M | 58.11M | 42.34M |
| Total liab | 13076.43M | 11086.80M | 8554.72M | 8696.84M | 7780.44M |
| Total stockholder equity | 6129.94M | 6096.64M | 5108.39M | 4822.12M | 4225.55M |
| Deferred long term liab | 1622.64M | 633.24M | 575.51M | 331.81M | 287.20M |
| Other current liab | 504.82M | 407.60M | 389.97M | 453.24M | 411.71M |
| Common stock | 119.60M | 119.60M | 119.60M | 119.60M | 119.60M |
| Capital stock | 119.60M | 1030.33M | 1030.33M | 1030.33M | 1030.33M |
| Retained earnings | 208.28M | 182.80M | 618.55M | 488.32M | 459.89M |
| Other liab | 2051.73M | 682.36M | 627.75M | 544.20M | 502.61M |
| Good will | 7011.91M | 6228.90M | 5332.27M | 5507.06M | 5209.23M |
| Other assets | 1930.41M | 882.61M | 812.55M | 564.25M | 505.43M |
| Cash | 547.98M | 655.49M | 579.65M | 741.98M | 1033.79M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1955.85M | 3474.31M | 1335.14M | 1366.56M | 1257.32M |
| Current deferred revenue | 37.83M | 43.54M | 23.98M | 10.64M | 15.53M |
| Net debt | 9202.15M | 8668.81M | 6331.75M | 6364.91M | 5254.91M |
| Short term debt | 681.27M | 2394.18M | 319.57M | 320.80M | 268.20M |
| Short long term debt | 578.92M | 2345.61M | 276.93M | 276.40M | 264.85M |
| Short long term debt total | 9750.12M | 9324.31M | 6911.40M | 7106.89M | 6288.71M |
| Other stockholder equity | 748.51M | 746.54M | 866.99M | 861.14M | 855.29M |
| Property plant equipment | 4168.49M | 3343.15M | 3002.80M | 2863.40M | 1951.98M |
| Total current assets | 4653.59M | 5510.28M | 3164.95M | 5362.18M | 3483.25M |
| Long term investments | 2548.89M | 2359.97M | 1980.06M | 143.98M | 228.82M |
| Net tangible assets | -2208.47700M | -1135.96800M | -1206.01400M | -1786.67000M | -2082.00800M |
| Short term investments | 43.26M | 2029.11M | 10.86M | 1727.43M | 0.82M |
| Net receivables | 754.82M | 495.48M | 504.20M | 470.50M | 401.57M |
| Long term debt | 8154.26M | 6104.97M | 5900.97M | 6089.80M | 6010.97M |
| Inventory | 3201.36M | 2259.35M | 2002.28M | 2342.59M | 1949.36M |
| Accounts payable | 731.92M | 628.99M | 601.62M | 581.88M | 561.88M |
| Total permanent equity | - | - | - | 0.00000M | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | 0.00000M | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | 0.00000M | 0.00000M |
| Accumulated other comprehensive income | 5053.55M | 5047.70M | 3503.25M | 3353.05M | 2790.77M |
| Additional paid in capital | - | - | - | 0.00000M | 0.00000M |
| Common stock total equity | - | - | - | 0.00000M | 0.00000M |
| Preferred stock total equity | - | - | - | 0.00000M | 0.00000M |
| Retained earnings total equity | - | - | - | 0.00000M | 0.00000M |
| Treasury stock | - | - | - | 0.00000M | 0.00000M |
| Accumulated amortization | - | - | - | 0.00000M | 0.00000M |
| Non currrent assets other | 54.06M | 4.14M | - | 10180.43M | 211.37M |
| Deferred long term asset charges | - | - | - | 0.00000M | 0.00000M |
| Non current assets total | 16880.39M | 13723.56M | 12109.82M | 10180.43M | 8993.80M |
| Capital lease obligations | 1016.94M | 873.72M | 733.50M | 740.69M | 12.88M |
| Long term debt total | - | - | - | 0.00000M | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -1978.82300M | 9.82M | -27.23800M | -31.81600M | 37.16M |
| Change to liabilities | 80.21M | 40.45M | -2.31900M | -44.54400M | 135.26M |
| Total cashflows from investing activities | -1978.82300M | -29.39300M | -858.11500M | -548.78900M | -781.86700M |
| Net borrowings | -177.37200M | 1878.52M | -243.37300M | -7.51500M | 37.42M |
| Total cash from financing activities | -173.49300M | 1472.92M | -354.40100M | -332.35600M | 152.50M |
| Change to operating activities | -9.01000M | -7.07500M | -20.60000M | -13.87100M | -3.09200M |
| Net income | 361.26M | 350.45M | 878.63M | 817.10M | 725.84M |
| Change in cash | -2127.63200M | 2095.96M | -162.33500M | -291.81000M | 147.27M |
| Begin period cash flow | 2675.61M | 579.65M | 741.98M | 1033.79M | 886.52M |
| End period cash flow | 547.98M | 2675.61M | 579.65M | 741.98M | 1033.79M |
| Total cash from operating activities | -10.86700M | 596.98M | 1110.34M | 568.93M | 737.43M |
| Issuance of capital stock | - | - | - | - | 0.00000M |
| Depreciation | 407.86M | 359.77M | 321.53M | 302.45M | 228.61M |
| Other cashflows from investing activities | - | - | - | 0.00000M | 0.00000M |
| Dividends paid | -0.59200M | -258.94600M | -113.23000M | -238.74000M | 278.84M |
| Change to inventory | -600.24500M | -157.47400M | 164.63M | -323.74800M | -231.67000M |
| Change to account receivables | -80.17000M | -16.80600M | -35.42900M | -99.37400M | -13.14100M |
| Sale purchase of stock | -3.45900M | -125.70300M | - | 0.00000M | 0.00000M |
| Other cashflows from financing activities | -65.15500M | 1940.26M | 110.74M | 33.98M | 573.28M |
| Change to netincome | -17.79100M | 195.31M | 63.97M | 122.87M | 24.82M |
| Capital expenditures | 375.56M | 315.09M | 362.56M | 412.31M | 307.72M |
| Change receivables | - | - | - | 0.00000M | 0.00000M |
| Cash flows other operating | - | - | - | 0.00000M | 0.00000M |
| Exchange rate changes | - | - | - | 0.00000M | 0.00000M |
| Cash and cash equivalents changes | - | - | - | 0.00000M | 0.00000M |
| Change in working capital | -609.21900M | -140.90800M | 106.28M | -481.53700M | -112.63900M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | -170.76900M | 27.66M | -196.10900M | -69.08800M | -104.38400M |
| Free cash flow | -386.42700M | 281.89M | 747.78M | 156.63M | 429.71M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GIFOF Grifols S.A |
- -% | 6.98 | 231.75 | 9.57 | 1.38 | 0.94 | 3.13 | 31.98 |
| LLY Eli Lilly and Company |
2.59 0.34% | 774.59 | 103.14 | 46.73 | 16.88 | 48.24 | 17.43 | 69.11 |
| JNJ Johnson & Johnson |
-0.525 0.36% | 144.09 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
0.72 0.41% | 178.42 | 61.52 | 14.86 | 5.62 | 51.62 | 6.76 | 20.58 |
| MRK Merck & Company Inc |
-0.3264 0.33% | 99.15 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Avinguda de la Generalitat, 152, Barcelona, Spain, 08174
| Name | Title | Year Born |
|---|---|---|
| Mr. Steven Francis Mayer J.D. | Exec. Chairman | 1960 |
| Mr. Raimon Grifols Roura | Co-CEO & Exec. Director | 1964 |
| Mr. Víctor Grifols Deu | Co-CEO & Exec. Director | 1977 |
| Mr. Alfredo Arroyo Guerra | CFO & VP | 1958 |
| Mrs. Eva Bastida Tubau | Corp. VP and Director of Scientific & Medical Affairs | NA |
| Ms. Nuria Pascual Lapeña | VP of Corp. Treasury, Risk Management Investor Relation & Sustainability Officer | 1964 |
| Mr. David Ian Bell | Gen. Counsel & Chief Corp. Devel. Officer | 1954 |
| Mr. Mateo Florencio Borrás Humbert | Corp. VP & Chief HR Officer | 1956 |
| Ms. Maria Teresa-Rioné Llano | Chief Communications Officer | 1965 |
| Ms. Montserrat Gaja Llamas | Chief HR Officer | 1965 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...